Fahir Özkalemkaş

ORCID: 0000-0001-9710-134X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Antifungal resistance and susceptibility
  • Lymphoma Diagnosis and Treatment
  • Fungal Infections and Studies
  • Neutropenia and Cancer Infections
  • Multiple Myeloma Research and Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Platelet Disorders and Treatments
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Hematopoietic Stem Cell Transplantation
  • CNS Lymphoma Diagnosis and Treatment
  • Blood groups and transfusion
  • Complement system in diseases
  • Blood disorders and treatments
  • Hematological disorders and diagnostics
  • Eosinophilic Disorders and Syndromes
  • Hemoglobinopathies and Related Disorders
  • Cutaneous lymphoproliferative disorders research
  • Viral-associated cancers and disorders
  • Peptidase Inhibition and Analysis
  • Bone and Joint Diseases
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Kruppel-like factors research

Bursa Uludağ Üni̇versi̇tesi̇
2016-2025

Creative Commons
2024

Sağlık Bilimleri Üniversitesi
2020-2022

Adli Tıp Kurumu
2021

Ergani Devlet Hastanesi
2021

Ufuk University
2020

Kocaeli Üniversitesi
2015

10.1016/s0140-6736(21)00592-4 article EN The Lancet 2021-06-01

Although bone marrow metastases can be found commonly in some malignant tumors, diagnosing a nonhematologic malignancy from is not usual event.To underscore the value of aspiration and biopsy as short cut establishing diagnosis for disseminated we reviewed 19 patients with malignancies who initially had marrow.The main indications examination were microangiopathic hemolytic anemia (MAHA), leukoerythroblastosis (LEB) unexplained cytopenias. Bone was diagnostic due to dry tap or inadequate...

10.1186/1471-2407-5-144 article EN cc-by BMC Cancer 2005-11-01

Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and single CD3-binding fragment. Encouraging response survival rates were recently reported in pivotal phase II expansion trial conducted patients relapsed/refractory (R/R) B-cell lymphoma. However, real-world data of all ages no strict selection criteria are still lacking. Herein, this retrospective study aimed evaluate outcomes diffuse large lymphoma (DLBCL) who received glofitamab via...

10.1002/hon.3174 article EN cc-by-nc-nd Hematological Oncology 2023-05-22

Background Febrile neutropenic patients are at high risk for developing invasive fungal infection (IFI). Currently, two treatment strategies, empiric and preemptive, used in febrile with IFI. This study aimed to evaluate empirical preemptive strategies high-risk hematologic malignancies. Methods We retrospectively analyzed 402 attacks 281 hematological malignancies hospitalized a university hospital hematology clinic. Between June 2006 January 2009, 154 episodes of 104 who met the...

10.46310/tjim.1602618 article EN cc-by-nc-nd Turkish Journal of Internal Medicine 2025-01-28

Aims: It was aimed at measuring the comorbidities of chronic myeloid leukemia (CML) patients time diagnosis with different comorbidity indices and evaluating their effects on disease prognosis. Methods: The were retrospectively screened calculated in three indices: ACE-27 Comorbidity Index, Age-adjusted Charlson Elixhauser Index. C-statistic used to evaluate ability discriminate mortality. relationship between scores overall survival (OS) evaluated Kaplan-Meier curve. Mortality risk analyzed...

10.1177/20406207251323701 article EN cc-by-nc Therapeutic Advances in Hematology 2025-01-01

Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease. Supportive treatments, such as erythropoiesis-stimulating agents (ESAs), are commonly used in patients with low-risk MDS. This study aimed to retrospectively assess the impact of bone marrow Mothers against decapentaplegic homolog 7 (SMAD-7) and Transforming Growth Factor Beta 1 (TGF-β1) protein expression on prognosis response ESA treatment We analyzed diagnosed MDS at adult hematology department Bursa Uludağ...

10.17305/bb.2025.11564 article EN cc-by Biomolecules and Biomedicine 2025-03-03

Background/Objectives: Low bone mineral density (BMD) is common in hemophilia patients. Identifying high-risk patients for low BMD early essential to prevent complications and reduce morbidity. The parathyroid hormone (PTH)/calcium (Ca) ratio a cost-effective marker predicting BMD, highlighting the need routine screening intervention this population. Hemophilia hereditary bleeding disorder caused by deficiencies clotting factors VIII (hemophilia A) IX B). Patients with are at risk of (BMD)....

10.3390/diagnostics15050638 article EN cc-by Diagnostics 2025-03-06

Background: Several thrombotic risk assessment models have been proposed for identifying patients with a high of thrombosis (the IMPEDE venous thromboembolism (VTE), SAVED, and PRISM scores) in multiple myeloma (MM). Recently, adding biomarker (D-dimer) the VTE score has shown that it can boost detection power IMPEDED VTE. However, data from studies comparing these MM are scarce. Even real-world arguing utility low- or middle-income countries like Türkiye lacking. Methods: We aimed to show...

10.3390/diagnostics15050633 article EN cc-by Diagnostics 2025-03-05

Therapeutic plasma exchange (TPE) is a prominent approach for specific conditions among renal transplant candidates and recipients. The indications of TPE, those related to kidney transplantation, are limited, knowledge utilization strategies blurred. Herein, we aimed review our clinical experience TPE A total 69 (40.22 ± 12.29 years, 40 males, 63.8% deceased donor) ABO blood type-compatible recipients who underwent were evaluated between January 2013 December 2019. median 5 (IQR 4-7)...

10.1111/1744-9987.70002 article EN Therapeutic Apheresis and Dialysis 2025-03-04

Abstract The impact of inflammatory markers such as systemic immune-inflammation (SII) index and inflammation response (SIRI) on myelofibrosis (MF) prognosis was evaluated for the first time in this study. Data from 60 patients diagnosed with MF between March 2011 September 2022 were retrospectively analyzed. In addition to disease-related markers, SII SIRI evaluated. our study, overall median survival (OS) 64 months. OS significantly shorter older than 65 years, high ferritin lymphocyte...

10.1038/s41598-023-39077-7 article EN cc-by Scientific Reports 2023-08-02

Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high 90% using current treatment protocols, prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at time diagnosis an unmet clinical need. Endothelial activation and stress index (EASIX) its variant modified EASIX (mEASIX) scoring system currently used prediction in hematologic malignancies. This study aimed to investigate prognostic value mEASIX...

10.3390/diagnostics15020185 article EN cc-by Diagnostics 2025-01-14

Kinürenin yolağı, yol boyunca oluşan metabolitler ve enzimler aracılığıyla neredeyse tüm bağışıklık tepkileriyle etkileşime girmektedir. Hız sınırlayıcı enzim olan indolamin 2,3-dioksijenaz (IDO), yolağın başlangıç adımında oksidoredüktaz olarak görev yapmakta olup triptofanın kinürenine dönüşümünü katalizler çeşitli enfeksiyöz hastalıkların patogeneziyle ilişkilendirilmiştir. Bu çalışmada, koronavirüs hastalığı 2019 [coronavirus diseases-2019 (COVID-19)] hastalarının serum IDO-1 düzeyleri,...

10.5578/mb.2025131 article TR Mikrobiyoloji Bulteni 2025-04-20

This study aimed to evaluate the efficacy and safety of eltrombopag in outpatient clinic Department Hematology, Uludag University Faculty Medicine. Treatment responses demographic characteristics 25 patients diagnosed with refractory chronic immune thrombocytopenia (ITP) receiving between January 2011 March 2014 were analyzed retrospectively. Both platelet ≥30,000/mm³ ≥50,000/mm³ values considered as responses. Prolonged response was defined maintenance 50,000/mm³ for 12 weeks or longer...

10.32708/uutfd.1635651 article EN cc-by-nc-nd Uludağ Üniversitesi Tıp Fakültesi Dergisi 2025-05-27

Primary cardiac lymphoma (PCL) is an extremely rare disorder. In this report, a 57-year-old male with diffuse large B-cell involving the heart and great vessels presented. Trans-thoracic echocardiography was first modality used to establish diagnosis. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) showed increased metabolic activity of walls hypermetabolic lesions occupying chambers in some areas. The patient underwent systemic chemotherapy,...

10.1093/ejechocard/jep111 article EN European Journal of Echocardiography 2009-09-15

Abstract Myelodysplastic syndrome (MDS) is a heterogeneous spectrum of clonal hematopoietic disorders with varying degrees cytopenia and morphologic dysplasia. The hemoglobin, albumin, lymphocyte, platelet (HALP) score prognostic marker in several types malignant tumors. Prognostic value HALP remains unclear for MDS. To determine the baseline We retrospectively analyzed data from 130 newly diagnosed MDS patients evaluated classified under score. By receiver operating characteristic (ROC)...

10.1038/s41598-024-64166-6 article EN cc-by Scientific Reports 2024-06-15

We aimed to assess the effectiveness, benefits, and reliability of percutaneous vertebroplasty (PV) in patients with vertebral involvement multiple myeloma.PV procedures performed on 166 vertebrae 41 myeloma were retrospectively evaluated. Most our using level 3 (moderate severe pain) analgesics. Magnetic resonance imaging was before procedure myeloma. The following variables evaluated: affected levels, loss body height, polymethylmethacrylate (PMMA) cement amount applied during PV, PMMA...

10.5152/dir.2016.15201 article EN Diagnostic and Interventional Radiology 2016-02-25
Coming Soon ...